Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population

Hoon Choi, Jae Young Park, Ji Sung Shim, Jae Heon Kim, Jae Hyun Bae

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: To investigate the efficacy of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) for the estimation of prostate volume (PV) in pathologically-proven benign prostatic hyperplasia (BPH) patients. Methods: From January 2010 to March 2013, 165 Korean men with a PSA less than 10 ng/mL who were diagnosed without prostate cancer by prostate biopsy were enrolled. Patients were classified into three age groups: ≤60, 61-70, and >70 years old. The results were organized to estimate and compare the ability of serum tPSA and fPSA to assess the PV. Results: Enrolled patients had a median age of 63.5 years (44 to 80), a median tPSA of 5.72 ng/mL, a median fPSA of 0.98 ng/mL and a median PV of 53.68 mL, respectively. Among the associations between tPSA, fPSA, age, and PV, the highest correlation was verified between fPSA and PV (r=0.377, P<0.0001); the correlation coefficient between tPSA and PV was much lower (r= 0.262, P<0.001). All stratified age cohorts showed the same findings. The ROC curves (for PV greater than 30, 40, and 50 mL) showed that fPSA (area under the curve [AUC]=0.781, 0.718, and 0.700) outperformed tPSA (AUC=0.657, 0.583, and 0.67) in its ability to predict clinically significant PV enlargement. Conclusion: Both tPSA and fPSA significantly correlated with PV in Korean men, while the correlation efficiency between fPSA and PV was more powerful. fPSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.

Original languageEnglish
Pages (from-to)73-77
Number of pages5
JournalInternational Neurourology Journal
Volume17
Issue number2
DOIs
Publication statusPublished - 2013 Aug 2

Fingerprint

Prostate-Specific Antigen
Prostate
Population
Aptitude
Prostatic Hyperplasia
Area Under Curve
Prostatic Neoplasms
ROC Curve

Keywords

  • Organ volume
  • Prostate-specific antigen
  • Prostatic hyperplasia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Urology

Cite this

@article{00e066296e0048e4a15f548f35e89a42,
title = "Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population",
abstract = "Purpose: To investigate the efficacy of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) for the estimation of prostate volume (PV) in pathologically-proven benign prostatic hyperplasia (BPH) patients. Methods: From January 2010 to March 2013, 165 Korean men with a PSA less than 10 ng/mL who were diagnosed without prostate cancer by prostate biopsy were enrolled. Patients were classified into three age groups: ≤60, 61-70, and >70 years old. The results were organized to estimate and compare the ability of serum tPSA and fPSA to assess the PV. Results: Enrolled patients had a median age of 63.5 years (44 to 80), a median tPSA of 5.72 ng/mL, a median fPSA of 0.98 ng/mL and a median PV of 53.68 mL, respectively. Among the associations between tPSA, fPSA, age, and PV, the highest correlation was verified between fPSA and PV (r=0.377, P<0.0001); the correlation coefficient between tPSA and PV was much lower (r= 0.262, P<0.001). All stratified age cohorts showed the same findings. The ROC curves (for PV greater than 30, 40, and 50 mL) showed that fPSA (area under the curve [AUC]=0.781, 0.718, and 0.700) outperformed tPSA (AUC=0.657, 0.583, and 0.67) in its ability to predict clinically significant PV enlargement. Conclusion: Both tPSA and fPSA significantly correlated with PV in Korean men, while the correlation efficiency between fPSA and PV was more powerful. fPSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.",
keywords = "Organ volume, Prostate-specific antigen, Prostatic hyperplasia",
author = "Hoon Choi and Park, {Jae Young} and Shim, {Ji Sung} and Kim, {Jae Heon} and Bae, {Jae Hyun}",
year = "2013",
month = "8",
day = "2",
doi = "10.5213/inj.2013.17.2.73",
language = "English",
volume = "17",
pages = "73--77",
journal = "International Neurourology Journal",
issn = "2093-4777",
publisher = "Korean Association of Medical Journal Edirors",
number = "2",

}

TY - JOUR

T1 - Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population

AU - Choi, Hoon

AU - Park, Jae Young

AU - Shim, Ji Sung

AU - Kim, Jae Heon

AU - Bae, Jae Hyun

PY - 2013/8/2

Y1 - 2013/8/2

N2 - Purpose: To investigate the efficacy of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) for the estimation of prostate volume (PV) in pathologically-proven benign prostatic hyperplasia (BPH) patients. Methods: From January 2010 to March 2013, 165 Korean men with a PSA less than 10 ng/mL who were diagnosed without prostate cancer by prostate biopsy were enrolled. Patients were classified into three age groups: ≤60, 61-70, and >70 years old. The results were organized to estimate and compare the ability of serum tPSA and fPSA to assess the PV. Results: Enrolled patients had a median age of 63.5 years (44 to 80), a median tPSA of 5.72 ng/mL, a median fPSA of 0.98 ng/mL and a median PV of 53.68 mL, respectively. Among the associations between tPSA, fPSA, age, and PV, the highest correlation was verified between fPSA and PV (r=0.377, P<0.0001); the correlation coefficient between tPSA and PV was much lower (r= 0.262, P<0.001). All stratified age cohorts showed the same findings. The ROC curves (for PV greater than 30, 40, and 50 mL) showed that fPSA (area under the curve [AUC]=0.781, 0.718, and 0.700) outperformed tPSA (AUC=0.657, 0.583, and 0.67) in its ability to predict clinically significant PV enlargement. Conclusion: Both tPSA and fPSA significantly correlated with PV in Korean men, while the correlation efficiency between fPSA and PV was more powerful. fPSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.

AB - Purpose: To investigate the efficacy of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) for the estimation of prostate volume (PV) in pathologically-proven benign prostatic hyperplasia (BPH) patients. Methods: From January 2010 to March 2013, 165 Korean men with a PSA less than 10 ng/mL who were diagnosed without prostate cancer by prostate biopsy were enrolled. Patients were classified into three age groups: ≤60, 61-70, and >70 years old. The results were organized to estimate and compare the ability of serum tPSA and fPSA to assess the PV. Results: Enrolled patients had a median age of 63.5 years (44 to 80), a median tPSA of 5.72 ng/mL, a median fPSA of 0.98 ng/mL and a median PV of 53.68 mL, respectively. Among the associations between tPSA, fPSA, age, and PV, the highest correlation was verified between fPSA and PV (r=0.377, P<0.0001); the correlation coefficient between tPSA and PV was much lower (r= 0.262, P<0.001). All stratified age cohorts showed the same findings. The ROC curves (for PV greater than 30, 40, and 50 mL) showed that fPSA (area under the curve [AUC]=0.781, 0.718, and 0.700) outperformed tPSA (AUC=0.657, 0.583, and 0.67) in its ability to predict clinically significant PV enlargement. Conclusion: Both tPSA and fPSA significantly correlated with PV in Korean men, while the correlation efficiency between fPSA and PV was more powerful. fPSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.

KW - Organ volume

KW - Prostate-specific antigen

KW - Prostatic hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=84880805658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880805658&partnerID=8YFLogxK

U2 - 10.5213/inj.2013.17.2.73

DO - 10.5213/inj.2013.17.2.73

M3 - Article

C2 - 23869271

AN - SCOPUS:84880805658

VL - 17

SP - 73

EP - 77

JO - International Neurourology Journal

JF - International Neurourology Journal

SN - 2093-4777

IS - 2

ER -